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The clinical severity of the neurodegenerative disorder Spinal
Muscular Atrophy (SMA) is dependent on the levels of func-
tional Survival Motor Neuron (SMN) protein. Consequently, cur-
rent strategies for developing treatments for SMA generally focus
on augmenting SMN levels. To identify additional potential thera-
peutic avenues and achieve a greater understanding of SMN, we
applied in vivo, in vitro, and in silico approaches to identify genetic
and biochemical interactors of the Drosophila SMN homolog. We
identiﬁed more than three hundred candidate genes that alter an
Smn-dependent phenotype in vivo. Integrating the results from
our genetic screens, large-scale protein interaction studies and
bioinformatics analysis, we deﬁne a unique interactome for SMN
which provides a knowledge base for a better understanding of
SMA.
Genetic screen j Interactome j Proteomics j Spinal Muscular Atrophy
j Survival Motor Neuron
INTRODUCTION
Spinal Muscular Atrophy (SMA), the leading genetic cause of
infant mortality, results from the partial loss of Survival Motor
Neuron (SMN) gene activity (1). Numerous studies indicate that
SMN functions as a central component of a complex which is re-
sponsible for the assembly of spliceosomal small nuclear ribonu-
cleoproteins (snRNPs) [reviewed in (2)]. SMN is also reported
to play additional roles, including mRNA trafficking in the axon
(3). In humans, SMN is encoded by two nearly identical genes,
SMN1andSMN2,whicharelocatedonchromosome5(4). SMN2
differs from SMN1 in that only 10% of SMN2 transcripts pro-
duce functional SMN due to a single nucleotide polymorphism
that results in inefficient splicing of exon 7 and translation of a
truncated, unstable SMN protein (1, 5, 6). The clinical severity of
SMA correlates with SMN2 copy number, which varies between
individuals (7). As the small amount of functional SMN2 protein
produced by each copy is capable of partially compensating for
the loss of the SMN1 gene function, higher copy numbers of
SMN2typicallyresultinmilderformsofSMA.Therefore,genetic
modifiers capable of increasing the abundance and/or specific
activity of SMN hold promise as therapeutic targets.
The Drosophila genome harbors a single, highly conserved
ortholog of SMN1/2, the Survival motor neuron (Smn) gene. SMN
is essential for cell viability in vertebrates and Drosophila (8, 9).
In Drosophila, zygotic loss of Smn function results in recessive
larval lethality (not embryonic as might be expected) due to the
rescue of early development by maternal contribution of Smn.
The larval phenotype includes neuromuscular junction (NMJ)
abnormalities that are reminiscent of those associated with the
human disease, rendering this invertebrate organism an excellent
system to model SMN biology (10-12). We previously described
a genetic screen for modifiers of the lethal phenotype resulting
from a complete loss of function Smn allele (13). This screen,
though it probed half of the Drosophila genome, identified only a
relativelysmallnumberofgenesthataffectedtheNMJphenotype
associated with Smn loss of function (13). In particular, it did
not identify genes involved in snRNP biogenesis, the molecular
functionality that is most clearly associated with SMN.
As the human disease state results from partial loss of SMN
function, we reasoned that a screening paradigm using a hypo-
morphicSmnbackground,(asopposedtoabackgroundthatcom-
pletely eliminates SMN function) would more closely resemble
the genetic condition in SMA. Such a screen would therefore
enhance our ability to detect novel elements of the Smn genetic
network, and, consequently, add significantly to our efforts to
both dissect the Smn genetic circuitry as well as identify potential
clinically relevant targets with novel mode of action.
This complementary screen proved to be more sensitive than
our previous screen and led to the identification of over 300
genetic interactors. Taking advantage of the recently established
Drosophila Protein Interaction Map (DPiM) (14), we related
the newly identified genetic interactors to the SMN protein in-
teractome, producing an integrated Drosophila SMN biological
network. Finally, the Drosophila SMN network was evaluated
for its relevance to human biology by mapping Drosophila SMN
network genes to their human homologs, and analyzing the hu-
man network using computational biology tools. The projection
of the Drosophila SMN network derived from this study onto
the human network derived from prior knowledge provides a
rational basis for novel SMN functional hypotheses and network
Signiﬁcance
Spinal Muscular Atrophy (SMA), the leading genetic cause of
infant mortality, is a devastating neurodegenerative disease
causedbyreducedlevelsofSurvivalMotorNeuron(SMN)gene
activity. Despite well-characterized aspects of the involvement
of SMN in snRNP biogenesis, the gene circuitry affecting SMN
activity remains obscure. Here, we use Drosophila as a model
system to integrate results from large-scale genetic and pro-
teomic studies, and bioinformatics analyses to deﬁne a unique
SMN interactome to provide a basis for a better understanding
of SMA. Such efforts not only help dissect the Smn biology but
may also point to potential clinically relevant targets.
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Fig. 1. Genetic modiﬁers of Smn using pupal lethal-
ity to screen the Exelixis collection of transposon
insertions and their functional roles(A) tubulinGAL4
(tub-GAL4) directed expression of an inducible Smn-
RNAi construct (UAS-Smn-RNAi
FL26B) leads to a fully
penetrant pupal lethality where approximately 40%
of the pupae reach a pigmented developmental stage
(Control). The remaining 60% die at an earlier un-
pigmented developmental stage. Introduction of an
Smn deﬁciency into this background causes the entire
population of pupae to die at the unpigmented stage
(Smn deﬁciency), while ectopic Smn expression leads
to survival to adulthood of the vast majority of pupae
(Smn rescue). Introduction of previously isolated en-
hancers (d02492 and d09801) and suppressors (f05549
and c05057) of Smn (13) lead to quantitative changes
in the fractions of pigmented vs. unpigmented pupae.
(B) The screening strategy to identify genetic modi-
ﬁers of the Smn pupal lethality phenotype using the
Exelixis collection (illustrated for insertions on the 3
rd
chromosome). The lethal phase for all Smn Tb+ TE
(16) pupae in individual test crosses are scored and
compared to those observed in control crosses (more
survival = enhancers, more lethality = suppressors).
(C) Drosophila functional categories over-represented
in the genetic modiﬁer list. GO biological functions
with the highest signiﬁcance relate to known Smn
functions such as alternative splicing or SMA affected
processes (neuronal and muscular). Enrichment signif-
icance is expressed as the –log10 (p-values).
intervention points that carry potential for so far unexplored
clinical applications.
RESULTS
A genetic screen for modifiers of Smn-dependent lethality
We examined several Smn-RNAi strains to identify a hy-
pomorphic Smn allele that could be used to model SMA in
Drosophila more faithfully than alleles that completely abol-
ish Smn function. We identified a transgenic strain, UAS-Smn-
RNAi
FL26B (FL26B) that displays a less severe phenotype than the
allele used in our previous screen (13). Specifically, expression
of FL26B under the control of tubulinGAL4 (tubGAL4::FL26B)
results in late pupal lethality whereby approximately 50% of the
pupae reach a more mature (pigmented) developmental stage
prior to death (Figure 1A) than their less mature, unpigmented
siblings.
We determined that this phenotype, measured by the ratio of
pigmented to unpigmented pupae, is sensitive to Smn dosage, as
reducing or increasing Smn copy number in the tubGAL4::FL26B
genetic background resulted in enhancement or suppression,
respectively (Figure 1A). In addition, the ability of wild type Smn
(expressed by a UAS-Smn-GFP transgene) to rescue the lethality
indicatesthatthisphenotypedoesnotresultfromofftargetRNAi
effects. These results were corroborated using an independent
Smn RNAi strain. Finally, we demonstrated that previously iden-
tified Smn modifiers altered the Smn RNAi phenotype in the ex-
pected fashion (Figure 1A). Together, these results demonstrate
that the tubGAL4::FL26B phenotype is useful to detect changes
in Smn functional activity and is thus suitable assay on which to
baseamodifierscreenthatwilldefineanddissecttheSmngenetic
network.
Using this novel assay, we screened the Exelixis
collection of genome-wide insertional mutations
[https://drosophila.med.harvard.edu/ and (15, 16)] for dominant
modificationofthelethalityassociatedwiththetubGAL4::FL26B
strain (see Figure 1B for scheme) and identified nearly 1600
candidate strains. To eliminate false positives, all interacting
insertions were retested. Only those that were not lethal in
trans with tubGAL4 (13) and for which results could be clearly
repeated were finally designated as modifiers. From this analysis,
we identified 303 modifying strains (129 enhancers and 174
suppressors), which represents nearly 2% of the collection and
a greater than tenfold increase in hit recovery in comparison
to our previous screening method. As the genomic location of
some insertions in the Exelixis collection may be near multiple
coding regions, unambiguous gene assignments are not always
possible. Given this consideration, we determined that these 303
insertions potentially affected 340 Drosophila genes. In most
cases, single genes were affected by single insertions, though 14
genes scored in the screen were represented by 2 or more alleles.
No gene could be assigned for 36 of the 303 insertions. Careful
human to Drosophila homology mapping using a combination of
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Fig. 2. The extended Drosophila genetic sub-network The sub-network of proteins connected to Smn and its genetic modiﬁers in the Drosophila Protein
Interaction Map (DPiM). A total of 62 Smn genetic modiﬁers (diamonds with red border) are directly connected to 361 other proteins (circles), also known
as ﬁrst-degree neighbors through 3,800 interactions. The thickness of the gray lines connecting the proteins is proportional to the interaction score in the
DPiM. Proteins belonging to individual clusters with GO term enrichment are shown with different colors. Proteins colored gray are part of clusters that are
not enriched for any speciﬁc GO terms. Smn protein (indicated by an arrow head) itself is only connected to Nmdmc and shown as an interacting pair at the
bottom.
several prediction algorithms show that out of the 340 Drosophila genes, at least 229 have human orthologs. Since a fraction of
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Fig. 3. Human Smn genetic modiﬁers
networkIngenuity Pathway Analysis indicates
that about one-third of the human orthologs of
Drosophila Smn genetic modiﬁers (103 genes, green
circles) are connected in a network involving 282
interactions with other modiﬁers and SMN1/SMN2
(yellow). Different types of interactions are indicated
with distinct colored lines. A small number of
modiﬁers (19 genes) have only interactions with
other modiﬁers but not SMN1/SMN2 (4 pairs are
two human orthologs of the same Drosophila gene).
Nearly two-thirds of the modiﬁers (177 genes, not
shown) have no interactions that would connect
them to SMN1/SMN2 or other modiﬁers
these genes are represented by multiple paralogs, we identified
a total of 322 human genes corresponding to the 229 Drosophila
modifiers (see Materials and Methods, Dataset S1).
To assess the biological space covered by the novel Smn
modifierstheywereevaluatedusingtheDatabaseforAnnotation,
Visualization and Integrated Discovery (DAVID) (17, 18)
(http://david.abcc.ncifcrf.gov/), which identifies biological pro-
cesses statistically overrepresented in the set of genetic mod-
ifiers. Analysis of the Drosophila SMN network with DAVID
identified known SMN molecular activity (alternative splicing)
and SMN-dependent processes (“neuron differentiation”, “axon
guidance”, “axonogenesis”, “muscle organ development” and
“dendrite morphogenesis/development”) (Figure 1C) (13, 19).
The predominant processes enriched in the modifier set reflect
broad effects on morphogenesis and development reinforcing the
notion that Smn depletion has pleiotropic consequences.
Integration of Drosophila genetic and proteomic interactors
To determine whether the genetic modifiers are intercon-
nected through physical interactions, we placed them in the
context of the recently generated Drosophila Protein Interaction
Map (DPiM) (14). We first retrieved the set of proteins that
co-purify with Drosophila Smn in DPiM, and asked whether
any of the modifiers belong to this Smn sub-network. From all
Drosophila proteins tested, 8 form protein complexes with Smn
and interestingly one, NAD-dependent methylenetetrahydrofolate
dehydrogenase (Nmdmc), is also a genetic modifier. Expansion
of the Smn subnetwork to include proteins that form complexes
with each of the eight members in turn identified 35 additional
proteins. Some of these proteomic interactors have been previ-
ously associated with Smn function (e.g. Gemin2, Gemin3 and
severalsnRNPs),andnearlyhalf(20/43)areknowntobeinvolved
in mRNA processing, a functionality closely linked to the docu-
mented biochemical role of SMN (Figure S1, Dataset S2).
Tobetterunderstandthebiologicalfunctionsidentifiedbythe
Smn modifiers, we extracted the Drosophila protein complexes,
which include the Smn genetic modifiers in DPiM. We found that
62 of the proteins corresponding to genetic modifiers passed the
stringent statistical criteria necessary for inclusion in the DPiM
interactome (Materials and Methods) which includes only the
top 5% of the total interactions scored in the coAP/MS analy-
sis. These 62 proteins were associated with 50 separate Markov
clusters, a statistical definition of significantly associated proteins
(20), each of which may define a functional protein complex
(see Figure 2 for the sub network of complexes identified by this
analysis). Of these 50, we focused our attention on the 24 that are
enrichedforspecificbiologicalfunctionsbasedonGeneOntology
(GO) terms – a system that provides a controlled vocabulary of
terms for describing gene cellular and molecular functions (21).
The majority of these clusters harbor a single modifier, but 9
contained two or more (Table S3).
Inspecting the GO biological function terms of these 24
clusters (annotated in Figure 2), we find that many contain
annotated functions previously linked to Smn activity including
RNA metabolism (“RNA splicing”, “mRNA binding”) [reviewed
in (3)], translation control (“eIF3 complex”) (22-25), endocy-
tosis (“Snap/SNARE complex”) (26, 27), and protein transport
(“flotillin complex”) (28-30). Importantly, several genetic mod-
ifiers fall within protein complexes whose functions have not
been previously associated with Smn function. These include
complexes with phosphatase and kinase activities as well as those
involved in intracellular signaling (“Toll signaling pathway” and
“Hedgehog signaling”) (Figure 3B). Two independent loss-of-
function alleles of the Ect4/dsarm gene suppress Smn dependent
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Fig. 4. Extended human Smn genetic sub-network Adding SMN1/2 ﬁrst-degree neighbors to the network shown in Figure 3 generated an extended sub-
network. In this interactome, 151 human orthologs of Drosophila Smn genetic modiﬁers (green circles) directly or indirectly connected to SMN1/SMN2. A total
of 48 modiﬁers are connected to SMN1/SMN2 through 71 additional intermediate proteins (pink circles) from literature, seven among them (blue circles) were
also identiﬁed in replicate SMN bait puriﬁcations in Drosophila. Different types of interactions are indicated with distinct colored lines
lethality. The recovery of Ect4/dsarm may provide additional evidence linking the Toll signaling pathway to Smn activity as it
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Fig. 5. Network of 36 high-priority genetic interac-
tors of SmnThe network shows 36 human orthologs
of Drosophila Smn genetic modiﬁers (green circles)
connected to SMN1/SMN2 in human. These 36 modi-
ﬁers are present in Drosophila DPiM as well as human
IPA based network and were selected for functional
validation in NMJs. The intermediate proteins (pink
circles) shown provide the shortest path to connect
the modiﬁers to SMN1/SMN2. Different types of in-
teractions are indicated with distinct colored lines.
Fig. 6. Genetic modiﬁers of Smn regulate NMJ
morphology. (A) An NMJ derived from muscle 6/7 of
a tubulinGAL4::UAS-Smn-RNAi
FL26B (tubGAL4::FL26B)
3
rd instar larva. (B, C) A reduction in NMJ size is
observed upon introduction of enhancers c024569 (B)
and d02738 (C) into the tubGAL4::FL26B background.
(D, E, F) Introduction of a suppressors c05501, c06705
into this screening background leads to an increase in
NMJ size, whereas suppressor d05711 (F) does not re-
sult in signiﬁcant modiﬁcation of the NMJ (G) Quanti-
tation of bouton numbers/muscle in individuals of in-
dicated genotypes, which include enhancers (red) and
suppressors (green), normalized per muscle surface
area (MSA) and expressed as percentage change as
compared to Tub Gal4:Smn RNAi alone. The ANOVA
multiple comparison test was used for statistical anal-
ysis of the bouton numbers/muscle. Signiﬁcance P<
0.05. Scale Bar = 50 mm. n = 20. All preparations were
stained with anti-HRP (red) and anti-Dlg (green). The
muscle nucleus was labeled using DAPI.
encodes a Toll/interleukin-1 receptor homology (TIR) domain.
Intriguingly, loss-of-function Ect4/dsarm mutations also suppress
Wallerian degeneration phenotypes observed in Drosophila and
mouse models (31). Together, these data suggest that the Wal-
lerian degeneration pathway may also affect Smn pathobiology,
an effect that may be mediated through Toll signaling. Hence this
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approach both confirmed and expanded the functional categories
and pathways associated with SMN.
To further explore the relationships of the 62 proteins and
their functional context within DPiM, we carried out a first-
degree neighbor analysis to identify other proteins directly con-
nected in the network that may represent potential biochemical
interactors. This retrieved 361 additional proteins that are linked
to the 62 Smn modifier interactors (Figure 2, Dataset S3). These
361 proteins include 128 that are directly linked to at least two
of the 62 modifiers (Table S3). A GO term (i.e. functionalities)
analysis of these proteins reveals additional connections to the
spliceosome, RNA binding and Snap/SNARE functions. Thus,
consideringgeneticmodifiersinthecontextoftheDPiMprovides
uswithanovelperspectiveofthediversemolecularfunctionsthat
can modulate SMN activity in vivo.
Overlaying the genetic modifiers on the human interactome
To study the Smn genetic circuitry in the human context, we
generated a human view of the genetic Smn interactome taking
advantage of the manually curated source of human molecular
interactionsfromIPA(Ingenuity®Systems,www.ingenuity.com).
Thisdatabaseintegrateshumangenerelationshipsderivedfroma
variety of experimental approaches, including proteomic studies.
Using the human Smn proteins and the 322 human genes cor-
responding to the genetic modifiers identified in Drosophila (see
above and Materials and Methods), we used the IPA knowledge-
base to derive a human SMN interaction network. Unlike DPiM,
IPA is not limited to physical interactions thus allowing consid-
eration of other functional interactions including, for example,
expression, localization, modification, and regulation. Such an
approach allowed us to evaluate potential indirect relationships
between the modifiers and SMN, and uncover molecular func-
tions beyond its canonical role in the SMN complex.
Based on the generated network, we found that orthologs
of five modifiers HNRNPR, SNRPD1, SYNCRIP, TRA2B and
ZNF259 are directly related to SMN1/2 (Figure 3). HNRNPR,
SNRPD1 and SYNCRIP proteins physically interact with SMN1
and 2 and have a role in RNA splicing (32). Trab2 (also known
as SFRS10 or Htra2-beta) was shown to regulate Smn2 protein
levels by being a potent splicing enhancer (33). Finally, ZNF259
also known as ZPR1 was shown to be necessary for the localiza-
tionofSmn1tonuclearbodies(34)andmorerecentlyemergedas
a key modifier of SMA pathology in patients (35). These findings
support the relevance of the identified Drosophila modifiers in
understanding the human pathways underlying SMA pathology.
Furthermore, 98 modifiers are indirectly related via these
five interactors to human SMN. Together these 103 proteins
representing one-third of the identified modifiers are intercon-
nected in a human IPA database. In addition, we find another
group of 19 proteins that make pair-wise functional interactions
with other SMN genetic modifiers, but do not connect to the
human Smn interactome. The remaining 177 proteins that are
not connected in the human interactome (and the 19 that have
pair-wise connections, 4 pairs of which are between two orthologs
of the same Drosophila gene) potentially represent functions that
have not been linked to SMN biology in human studies so far.
Expansion of the human SMN interactome beyond the 103
modifiers, by incorporating first-degree neighbor proteins of
SMNinthedatabase,connectsanadditional48modifiers(Figure
4). This expanded human SMN network contains intermediates
that are known to associate physically with SMN (GEMINs, HN-
RNPs and LSM and SNRP family members) (3, 14) and signaling
pathway elements known to affect SMN activity (FGF2, GSK3B,
MAP3K5) (19, 36-39).
Validation of genetic modifiers at the larval NMJ
We chose to prioritize the modifiers for further functional
characterization by using membership within both the Smn mod-
ifier network in DPiM (Figure S1) and the expanded IPA Human
SMN network (Figure 4) as the primary criterion. A total of 36
genes are shared between these interactomes (Figure 5, Dataset
S4). The list includes 4 previously analyzed modifiers (Actn,
Moes, Fim, cut up) (13, 27), 13 enhancers, (Sod, Hsp68, Hsf, step,
CG17838, ns1, shrb, VhaSFD, Rel, Hexo2, osa, CG13902, cathD)
and 19 suppressors (CG30194, Nedd4, Pka-R2, Rho1, Tango7,
Argk, 14-3-3-epsilon, Zpr1, CG9769, cenG1A, flw, comt, CG9062,
l(3)72Ab, Karybeta3, HmgZ, Rbsn-5, sel, Paip2).
Our previous analyses (13) indicated a strong correlation be-
tween the strength of the lethal Smn phenotype with the severity
of NMJ abnormalities. Therefore, examination of the effects of
Drosophila modifiers on the Smn NMJ phenotype was used to
validate their role in Drosophila and prioritize the corresponding
orthologs for further investigation in vertebrate model systems.
We used NMJ assays (13, 19) to sample the ability of a subset of
these modifiers to alter the tubGAL4::FL26B NMJ phenotype.
Examination of third instar larvae carrying a combination of
tubGAL4::FL26Bandeachof20modifierstrainsrevealedthat11
out of the 20 (55%) strains reveal a statistically significant change
in the number of synaptic boutons and are modifiers of the Smn
NMJ phenotype (Figure 6).
Effect of genetic modifiers on Smn protein levels and local-
ization
Given that the severity of the disease phenotypes, in both
patients and Drosophila models, correlates with SMN proteins
levels, we examined whether the prioritized genes affected SMN
levels in Drosophila S2R+ cells (40), the same cell line used
to generate DPiM. We used an image-based analysis (37) to
quantify SMN protein levels in S2R+ cells expressing inducible
FLAG-HAtaggedconstructscorrespondingto21Smnmodifying
genes available from the Universal Proteomics Resources (41).
Untransfected cells within the same wells were used as controls.
Surprisingly, we found that none of these ectopically expressed
modifier genes significantly altered total Smn protein expression
(Figure S2A). Since Smn is localized in both the cytoplasm and
the nucleus, we also used this assay to evaluate whether any
of these modifiers altered its distribution between these two
compartments. We found seven modifiers significantly increased
the nuclear Smn levels (Figure S2B and Dataset S5), consistent
with the notion that some modifiers from the screen, which affect
Smn lethality and NMJ phenotype, may directly affect Smn distri-
butionbetweenthenucleusandcytoplasm.Itisworthnotingthat,
a recent study (42) showed that mutant superoxide dismutase-
1 (SOD1), known to cause familial ALS, alters the sub-cellular
localization of the SMN protein and disrupts its recruitment to
Cajal bodies thereby preventing the formation of nuclear 'gems'.
Sod was identified in our screen as an enhancer and was also
shown to affect NMJ phenotype (Figure 6). A subset of modifiers
does not alter either Smn levels or its localization. How these
modifiersaffectthefunctionalSmnremainstobeexplored.Given
theseresults,however,itisimportanttonotethatsmallchangesin
SMNfunctionmayhaveanimportantbiologicalimpactgiventhat
the severity of clinical manifestation in SMA patients correlates
with small changes in SMN expression (1).
DISCUSSION
Different animal models for SMA-associated neuromuscular de-
fects contributed significantly to a better understanding of the
Spinal Muscular Atrophy etiology and genetics over the last few
years. However, despite the well-characterized role for SMN in
snRNP biogenesis, the links between its molecular function and
the defects observed in SMA patients remain unclear. One of the
key features of SMA is that the severity of the disease is depen-
dent on SMN dosage, prompting the development of therapeutic
strategies designed to increase SMN protein levels in patients.
Still, it is essential to identify alternative approaches to modulate
SMN activity. For this purpose, genetically tractable invertebrate
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systems may help to identify so far undiscovered elements of
the SMN genetic circuitry. In particular, these organisms provide
more flexible avenues to investigate the poorly understood role
of SMN at the NMJ.
We have used Drosophila as our experimental system and
previously described a genetic screen which uncovered a small
number of Smn modifiers (13) of a strong loss of function mutant
phenotype. In this screen, we identified functional links between
Smn and the FGF pathway (13, 19), a relationship corroborated
and extended by recent evidence in a severe mouse model of
SMA, which demonstrated widespread alterations of the FGF-
system in both muscle and spinal cord (38).
Therelativelysmallnumberofmodifiersrecoveredsuggested
a more sensitive genetic screen could provide extended informa-
tion about the Smn genetic network. Our assessment of the lethal
phaseexhibitedbyamildlossoffunctionSmnRNAiallele,which
more closely resembles the SMA hypomorphic condition, pro-
vided us with a more sensitive and quantifiable assay for genetic
interaction. In comparison to our previous results, the RNAi-
based screen described here provided us with a broader spectrum
of modifiers including those related to the canonical role of Smn
in snRNP biogenesis as well as additional elements of FGF and
BMP signaling (13). Our careful mining of the screening mod-
ifier list based on functional term enrichment, and interactome
analysis both in Drosophila and human, suggest that loss of Smn
function may impact a range of developmental and maintenance-
related programs of the whole neuromuscular system, including
synaptic vesicle recycling, ion channels and signaling pathways
that regulate intrinsic cellular functions. Finally, this analysis also
uncovered biological processes not previously associated with
Smn.
Among the newly recovered genes, many are associated with
RNA metabolism; however, the majority is not involved with
canonical SMN activity of snRNP biogenesis and includes fac-
tors involved in transcription, post-transcriptional modifications,
RNAtransportandtranslationregulation.Intriguingly,CG17838
is the Drosophila homolog of two closely related vertebrate RNA-
binding proteins, hnRNP-R and SYNCRIP/hnRNP-Q, both of
which bind to SMN in a yeast two-hybrid assay (32) and localize
to mRNA containing granules that are transported in cultured
neurons (28, 32, 43). Since both SMN and hnRNP-R affect lo-
calization of mRNA in axons (44, 45), this could have profound
consequences on local translation in neurons (45).
Giventhecomplexityofmotorneuronalsub-cellulardomains
and their distance from the neuromuscular synapses, local reg-
ulation of the translation of synaptic proteins is likely to be
important in synaptic plasticity and neurological diseases. In fact,
many mRNA binding proteins (RBPs) that function as key regu-
lators of local RNA translation are associated with neurological
diseases, including FMRP in Fragile X Syndrome, ATXN-2 in
Spinocerebellar Ataxia, and TDP-43, FUS (fused in sarcoma),
ANG and ATXN-2 in Amyotrophic Lateral Sclerosis. Consistent
with a possible role for Smn in affecting local translation, we
recovered pumilio and eIF-4E, which are thought to be a part
of the local translational apparatus in neuromuscular synapses
(46). Furthermore, we recovered another translation regulator,
eIF-4A, which negatively regulates BMP signaling components.
Components of BMP signaling pathway have been shown to play
a role in retrograde signaling in the NMJ (47, 48). Our results
support the relationship between Smn and local translation and
also provide an additional link to the retrograde signaling present
in the neuromuscular system. Interestingly, perturbation of RNA
translational control may result in defects in endocytosis (49, 50),
a process that has been suggested play a key role in neurode-
generative diseases, including Alzheimer’s (51) and Huntington’s
diseases (52). Consistent with this notion, aberrant synaptic vesi-
cle release at the NMJs in severe SMA mice may be evidence of
impaired synaptic vesicle dynamics and/or abnormal active zone
architecture (53). Further supporting a link between endocyto-
sis and Smn (27), we identified Synaptotagmin1, Synaptotagmin-
alpha, Syntaxin4 and comatose, the Drosophila homolog of N-
ethylmaleimide sensitive factor (NSF), which are core compo-
nents of synaptic vesicle recycling. We also recovered genes that
are directly required for synaptic transmitter release, such as
methuselah, or indirectly, such as bruchpilot, which plays a role
in constructing the active zone.
Though many of the recovered genes broadly impact the neu-
romuscularsystem,asubsetincludestheDrosophilahomologsfor
several disease related genes, including Nrx-1 (schizophrenia and
Autism Spectrum Disorders) (54, 55), Dystrophin (Duchenne’s
Muscular Dystrophy) (56, 57), Superoxide dismutase (42, 58),
RhoA, (Amyotrophic Lateral Sclerosis) (59) and Ect4/dSarm
(Wallerian degeneration) (31). Our recovery of these genes sug-
gests the genetic network identified by our screen may overlap,
perhaps significantly, the genetic networks impacted by other
human neurological disorders. If true, the use of Drosophila to
explore other neurological disease networks via genetic screens,
combined with the integration of additional genome-wide ap-
proaches, could identify common therapeutic targets which could
potentially be tested in other disease models.
Since such genetic modifier screens are very sensitive and
are able to recover a large number of modifiers that span a
broad range of molecular functions, prioritization of candidates
for further validation is essential. Here, bioinformatics mining
allowed us to assemble a list of 36 Drosophila genes with hu-
man homologs for continued investigation. The majority of these
tested genes showed a functional role in the structure and/or
development of the NMJ in Drosophila, and some can alter the
distribution of Smn in S2R+ cells, making them good candidates
to pursue in vertebrate models of SMA. In addition, candidates
may be drawn from a pool of modifiers that include members of
signaling pathways such as GPCR, Kinases and Proteases, which
are considered to be plausible small molecule targets, or secreted
or membrane proteins, which may be targeted by antibodies. Our
results thus provide an extensive list of novel genes and pathways
that have now been functionally linked to an Smn-dependent
phenotype and therefore represent potentially novel therapeutic
targets.
MATERIALS AND METHODS
Drosophila stocks and culture
All Drosophila stocks were maintained on standard Drosophila medium
at 25°C. The generation of the Smn alleles and constructs used in this
study (Smn
X7, UAS-Smn-RNAi
FL26B, UAS-Smn-GFP) were originally described
in (13). The tubulinGAL4 and TM6B, Tb Hu tubulinGAL80 chromosomes
used to generate the screening stock were obtained from the Bloomington
Drosophila Stock Center (Bloomington, IN). The Exelixis Collection is housed
in the Artavanis-Tsakonas laboratory in the Department of Cell Biology at
Harvard Medical School (Boston, MA).
Genetic Modiﬁer Screen
Individual strains from the Exelixis Collection were tested for the ability
to genetically modiﬁy the tubGAL4-induced UAS-Smn-RNAi
FL26B pupal lethal
phenotype by mating 3-5 males of the strain to 3 females of the w; UAS-
Smn-RNAi
FL26B; tubGAL4/TM6B, Hu Tb tubGAL80 screening stock. After two
days, adults were transferred to a fresh vial to create a duplicate cross and
to maintain optimal culture density. Accordingly, adults were discarded from
the duplicate after an additional two days had passed. 15 days after being
initiated, crosses were scored by counting the number of pigmented and
unpigmented Tb+ pupae along with any Hu+ adult escapers. The ratio of
unpigmented pupae to the total of pigmented pupae + escapers adults
was compared to that derived from control crosses using males from the
isogenic strain in which the Exelixis Collection was generated. Two control
crosses were performed for each set of approximately 100 strains that were
tested.Crossesthatfailedtoproduce40experimentalanimalswererepeated
as above. A change in the ratio of unpigmented to pigmented individuals
of 20% corresponded to an approximate 1.5 standard deviation from the
mean. Enhancers were deﬁned as those mutations causing a reduction in
this percentage (≤30%), while those that increased this percentage (≥70%)
were classiﬁed as suppressors.
Gene Assignments for the Exelixis Collection of Transposon Insertions
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Data for Drosophila genes and Exelixis transposon insertion sites were
obtained from FlyBase version 5.39, which was current as of August 2011. Of
the 15,952 Exelixis stocks screened, 14,621 stocks were mapped in FlyBase
to 15,326 transposons with speciﬁc insertion sites within the Drosophila
genome. To determine the coordinates of insertion sites of transposons
present in the remaining 331 strains, sequences from the region ﬂanking the
insertion sites (15) were searched against the Drosophila genome using the
blastn program of the Basic Local Alignment Search Tool [BLAST, (60)]. The
insertion sites of the transposons were then used to create gene assignments
according to the following criteria: a transposon was considered to map to
a particular gene if its insertion site is located in the transcription unit of the
gene itself or within either 1 kb upstream of the transcription start site or
100 bp downstream of the transcription termination site.
Mapping Drosophila genes to human orthologs
FlyBase version v5.39 identiﬁes 15,233 Drosophila genes, which were
iteratively mapped to human orthologs using predictions made by several
prediction algorithms. Multiple predictions were combined into a single
prediction by ordering the algorithms based upon lowest false positive and
highest false negative rates [see (61)], and choosing the ﬁrst prediction. The
methods used (in order) were inParanoid version 7 (62), orthoMCL version 5
(63), Homologene build 65 (64) and, orthoMCL version 2 (65). The inParanoid
predictions were selected using a probability score of 0.4. As a result, of the
15,233 Drosophila genes considered, 6,821 could be mapped to 6,703 human
gene ids. This dataset was used to assign the human orthologs of Drosophila
Smn modiﬁers as shown in Dataset S1.
Function and network analysis
The functional enrichment Gene Ontology terms of the Drosophila
genetic modiﬁers was assessed using EASE statistics available through the
Database for Annotation, Visualization, and Integrated Discovery (DAVID)
Bioinformatics Resources using the Exelixis collection as a reference set (17,
18). Human and Drosophila, protein-protein and genetic interactions were
visualized and analyzed (ﬁrst neighbors) using Cytoscape (66). Cytoscape
BinGo plugin was used to evaluate the Functional categories of the retrieved
clusters in the Drosophila sub-networks. The human network was generated
through the use of IPA (Ingenuity Systems, www.ingenuity.com) and further
visualized and mined in Cytoscape.
Neuromuscular junction analyses
Third instar larvae were dissected in cold 1X phosphate buffered saline
(PBS) and ﬁxed at room temperature (RT) for 20 min. in 4% Paraformalde-
hyde (PFA). The samples were washed in 0.1% Triton-X100 in PBS (PTX) and
incubated overnight at 4°C with primary antibody. The primary antibody was
washed off with PTX at RT. The samples were incubated at RT with secondary
antibody for 90 min. This was followed by PTX wash, and the tissues were
mounted in Vectashield Mounting Media with DAPI (Vector Laboratories).
Bouton numbers were counted using a Nikon TE2000 microscope, based
on the Discs large and anti-HRP staining in the A3 segment muscle 4 as
indicated. The muscle area for every animal was measured, and no signiﬁcant
difference was observed among different genotypes. At least 20-25 animals
of each genotype were dissected for the bouton analysis. The ANOVA
multiple comparison test was used for statistical analysis of the bouton
number/muscle.
Microscopy
All images were collected with a Nikon C1si spectral point scanning
confocal connected to a Nikon TE2000 inverted microscope equipped with
DIC, phase, and epi-ﬂuorescence optics, 40x Plan Fluor NA 1.4 objective lens
and the Perfect Focus System for continuous maintenance of focus. 100mW
mercury arc lamp illumination for viewing ﬂuorescence by eye, and confocal
scanning using Melles Griot solid state diode lasers: 405nm, 488nm (10mW),
and 561nm (10mW). The image acquisition software used was Nikon EZ-C1.
All samples were mounted and imaged in Vectashield mouting medium with
DAPI (Vector Laboratories) at room temperature. Adobe Photoshop CS5 was
used to pseudocolor images.
Analysis of Smn levels in S2R+ cells
Drosophila S2R+ cells (40), a derivative of Schneider S2 cells, were
cultured in Schneiders Drosophila medium (Gibco) with 10% fetal bovine
serum, 100 U/ml of penicillin, and 100 μg/ml of streptomycin at 25°C. FLAG-
HA constructs (Guruharsha et al., 2011) were transfected using TransIT-2020
(Mirus). One day after transfection, plasmid expression was induced with
0.35 mM CuSO4 overnight. Harvested cells were plated on concanavalin A
(0.5 mg/ml, Sigma) -coated plate and ﬁxed at room temperature for 20
min in 4% paraformaldehyde (Electron microscopy sciences). The cells were
washed in PBS-DT (0.3% sodium deoxycholate, 0.3% Triton X-100 in PBS) and
incubated overnight at 4°C with rabbit anti-Smn (1:2000) (Sen et al., 2011)
and mouse anti-Flag (1:1000, Sigma). After washes in PBS-DT, the cells were
incubatedwithmouseAlexa488-andrabbitAlexa568-conjugatedsecondary
antibodies (1:500, Molecular Probes), followed by washing in PBS-T (0.1%
Triton X-100 in PBS). The samples were mounted in VECTASHIELD mounting
medium with DAPI (Vector Laboratories).
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